Beijing Hotgen Biotech Co., Ltd. (SHA:688068)

Market Cap	6.37B -59.5%
Revenue (ttm)	469.17M +1.0%
Net Income	-259.44M
EPS	-2.79
Shares Out	88.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,733,250
Open	69.40
Previous Close	70.10
Day's Range	66.21 - 72.39
52-Week Range	67.06 - 214.78
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2026

About Beijing Hotgen Biotech

Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers nucleic acid drugs, antibody drugs, and biotechnology health and beauty consumer products. The company also provides clinical diagnostics and product solutions, including Upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestinal foodborne infectio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 1,043
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688068

Financial Performance

In 2025, Beijing Hotgen Biotech's revenue was 404.88 million, a decrease of -20.58% compared to the previous year's 509.78 million. Losses were -216.05 million, 4.99% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error